Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

550 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Novel designs and end points for phase II clinical trials.
Adjei AA, Christian M, Ivy P. Adjei AA, et al. Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276272 Review.
The future of phase II trials.
Farley J, Birrer MJ, Christian MC. Farley J, et al. Gynecol Oncol. 2006 Nov;103(2 Suppl 1):S20-2. doi: 10.1016/j.ygyno.2006.08.021. Epub 2006 Oct 4. Gynecol Oncol. 2006. PMID: 17027074 No abstract available.
Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials.
Christian MC, Trimble EL. Christian MC, et al. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):277s-283s. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646527 No abstract available.
A central institutional review board for multi-institutional trials.
Christian MC, Goldberg JL, Killen J, Abrams JS, McCabe MS, Mauer JK, Wittes RE. Christian MC, et al. N Engl J Med. 2002 May 2;346(18):1405-8. doi: 10.1056/NEJM200205023461814. N Engl J Med. 2002. PMID: 11986418 No abstract available.
Cancer treatment and the older patient.
Trimble EL, Christian MC. Trimble EL, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1956-7. doi: 10.1158/1078-0432.CCR-06-0364. Clin Cancer Res. 2006. PMID: 16609002 No abstract available.
NCI's cancer therapy evaluation program: a commitment to treatment trials.
Abrams JS, Murgo A, Christian MC. Abrams JS, et al. Cancer Treat Res. 2007;132:31-50. doi: 10.1007/978-0-387-33225-3_3. Cancer Treat Res. 2007. PMID: 17305016 Review. No abstract available.
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
Heath EI, LoRusso PM, Ivy SP, Rubinstein L, Christian MC, Heilbrun LK. Heath EI, et al. J Biopharm Stat. 2009;19(3):414-23. doi: 10.1080/10543400902800460. J Biopharm Stat. 2009. PMID: 19384685 Free PMC article.
Phase I clinical trial design in cancer drug development.
Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Eisenhauer EA, et al. J Clin Oncol. 2000 Feb;18(3):684-92. doi: 10.1200/JCO.2000.18.3.684. J Clin Oncol. 2000. PMID: 10653884
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA. Johnson JI, et al. Br J Cancer. 2001 May 18;84(10):1424-31. doi: 10.1054/bjoc.2001.1796. Br J Cancer. 2001. PMID: 11355958 Free PMC article.
The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growth inhibition below 10(-7.5) M were active in more than 6 intraperitoneal fibres whereas only 4% of compounds with a potency of 10(-4) …
The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56% of compounds with mean 50% growt …
550 results
Jump to page
Feedback